A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 25 Feb 2016
At a glance
- Drugs Terameprocol (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Erimos Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 20 Feb 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 29 Jan 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.